SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

InvestoGain Australia

Celebrating 20 Years in Business

Thank you for being part of our development since September 2001. With your ongoing support we look forward to many exciting developments ahead.

SEARCH LISTED COMPANY


Any AUS or NZ company

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

ANTISENSE THERAPEUTICS LIMITED(ANP)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of ANP: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Boardroom Pty Ltd, Level 12, 225 George Street, Sydney NSW 2000

Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000ANP4
Address: Level 1 14 Wallace Avenue TOORAK VIC 3142 AUSTRALIA
Tel:  +61 (0)3 9827 8999 Fax: +61 (0)3 9827 1166

Date first listed: 20/12/2001
Company Secretary: Phillip Hains, Alicia Mellors
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Create, develop and commercialise novel antisense therapeutics

News & Events

Expand this box to read and print

The suspension of trading in the securities of Antisense Therapeutics Limited will be lifted immediately, following the release by ANP of an announcement regarding clinical trial results.

17/12/2019

The data from all nine participants having completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy has affirmed the drug's excellent safety profile and positive drug effects on disease progression endpoints at the low dose tested and in turn the company's plans to advance ATL1102 into a potentially pivotal Phase IIb clinical trial.

17/12/2019

Antisense enters into an agreement with Morgans Corporate Limited to underwrite the balance of the options not yet exercised or committed, to raise $4.1 million. Total funds raised via the options exercise will be $5.5 million. Funds raised from the issue of the Options intended for use towards advancing plans for Phase IIb clinical trial of ATL1102 in DMD and for general working capital and corporate purposes.

17/12/2019

The securities of Antisense Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ANP, pending the release of an announcement regarding clinical trial results.

16/12/2019

we understand that on or about this date the company consolidated its shares 1 for 10

13/11/2013

The suspension of trading in the securities of Antisense Therapeutics Limited (the "Company") will be lifted immediately, following the release of an announcement by the company regarding a capital raising

23/03/2012

The securities of Antisense Therapeutics Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding a capital raising

23/03/2012
OFX Transferring Money Internationally to Free

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    20/12/2019Robert Moses100,000$0.088$8,800
    02/11/2018Mark Diamond157,856$0.037$5,803
    02/11/2018Robert Moses200,000$0.038$7,664
    25/07/2018Robert Moses278,928$0.026$7,252
    31/05/2018William Goolsbee170,843$0.025$4,271

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Robert MosesChairman23/10/2001
    Mark DiamondManaging Director, CEO31/10/2001
    Phillip HainsCFO09/11/2006
    Graham MitchellNon Exec Director24/10/2001
    Gary PaceNon Exec Director09/11/2015
    Charmaine GittlesonNon Exec Director22/03/2021
    Gil PriceNon Exec Director04/10/2021
    William GoolsbeeNon Exec Director15/10/2015
    Simon WatkinInvestor Relations

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Chris BelyeaNon Exec Director13/11/200012/11/2015
    George WertherNon Exec Director23/10/200102/11/2012
    Frank BennettNon Exec Director31/07/200615/03/2008
    Stanley CrookeNon Exec Director31/10/200131/07/2006

    Date of first appointment, title may have changed.